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Most anti-cancer immunotherapeutic strategies involving dendritic cells (DC) as vaccines rely upon the adoptive transfer of DC
loaded with exogenous tumour-peptides. This study utilized human acute myeloid leukemia (AML) cells as progenitors from
which functional dendritic-like antigen presenting cells (DLC) were generated, that constitutively express tumour antigens for
recognition by CD8+ T cells. DLC were generated from AML cell lines KG-1 and MUTZ-3 using rapid culture techniques and
appropriate cytokines. DLC were evaluated for their cell-surface phenotype, antigen uptake and ability to stimulate allogeneic
responder cell proliferation, and production of IFN-γ; compared with DC derived from normal human PBMC donors. KG-1 and
MUTZ-3 DLC increased expression of CD80, CD83, CD86, and HLA-DR, and MUTZ-3 DLC downregulated CD14 and expressed
CD1a. Importantly, both KG-1 and MUTZ-3-derived DLC promoted proliferation of allogeneic responder cells more eﬃciently
than unmodiﬁed cells; neither cells incorporated FITC-labeled dextran, but both stimulated IFN-γ production from responding
allogeneic CD8+ T cells. Control DC produced from PBMC using the FastDC culture also expressed high levels of critical cell
surface ligands and demonstrated good APC function. This paper indicates that functional DLC can be cultured from the AML
cell lines KG-1 and MUTZ-3, and FastDC culture generates functional KG-1 DLC.
1.Introduction
Manipulating the interactions between DC and na¨ ıve T cells
is an important part of the design of strategies for the
immunotherapy of both solid and hematological cancers [1].
In vitro, DC can be generated from CD34+ cells by culture
with cytokines such as GM-CSF, IL-4, Flt3L, CD40 ligand,
SCF,andTGF-β.AlternativelyDCcanbegrownfromCD14+
peripheral blood mononuclear cells (PBMC) during 5–9-
day culture, using GM-CSF and IL-4 [2]. DC maturation
is usually achieved with either TNF-α or lipopolysaccharide
(LPS). It was also reported that functional DC could be
cultured from PBMC using a combination of GM-CSF
and IL-4 for 24 hours followed by a combination of four
proinﬂammatory cytokines (TNF-α,I L - 1 β,I L - 6 ,a n dP G E 2)
f o raf u r t h e r2 4h o u r s[ 3].
We and others have previously reported that DC can be
cultured from leukemic blast cells [4–6]. In some cases either
autologous [6, 7]o ra l l o g e n e i c[ 5, 6] antileukemic cytotoxic
T lymphocytes (CTL) were generated. Alternatively, normal
DC are pulsed with leukemia antigens using either apoptotic
blasts or leukemic cell lysate, or DC-tumor cell hybrids are
used [1]. In addition, some available human leukemic cell
lines can be diﬀerentiated into DLC [8]. In this study we
have utilized AML cell lines for use as a source of DLC.
Importantly, this approach provides a uniform source of
DLC for further study.
Long-term DC culture protocols may increase exper-
imental cost and the possibility of contamination, and
optimized culture protocols have been investigated to eval-
uate the utility of shorter cultures which may minimize
microbiological contamination and be more economical.
Therefore, the culture of unselected normal PBMC using
the FastDC method described by Dauer et al. [3], and
“conventional” 7-day DC culture with GM-CSF and IL-4
were compared. Experiments were also carried out using2 Journal of Biomedicine and Biotechnology
optimized methods for the diﬀerentiation of DLC from
the human leukemia cell lines KG-1 and MUTZ-3, which
have myeloid and monocytic characteristics, respectively. In
this study, the term DLC has been restricted to the cells
obtained from leukemic cell line cells after DC culture.
Previous reports have shown that GM-CSF, IL-4, PMA,
and ionomycin were able to induce the formation of DLC
from KG-1 cells [9–11] whereas MUTZ-3 DLC are best
cultured using the more conventional combination of GM-
CSF, IL-4, and TNF-α over 5 days [12, 13]. Studying DLC
function could be vital to understand the biology of DC
and aid the development of immunotherapeutic strategies to
combat cancer. DLC transformation of cultured KG-1 and
MUTZ-3 cells was studied using FastDC and 7-day culture
methods. The cell-surface phenotypes of DC and DLC
were evaluated together with functional analysis of FITC-
conjugated dextran phagocytosis, stimulation of allogeneic
T-cell proliferation, and IFN-γ production.
2.MaterialsandMethods
2.1. Antibodies and Reagents. FITC-labeled anti-human
CD1a(HI149), CD80(L307.4), CD83(HB15e), HLA-ABC
(G46-2.6), HLA-DR(G46-6), and PE-labeled anti-human
CD11c(B-ly6), CDw123(9F5), CD14(M5E2), CD40(5C3),
CD54(HA58), CD8(HIT8a), and CD86(IT2.2) antibodies
were obtained from BD PharMingen (Cowley, UK). FITC-
and PE-labeled isotype control antibodies IgG1κ were
obtained from BD PharMingen. FITC-labeled dextran (mo-
lecular weight 40kDa) was purchased from Sigma-Aldrich
(Poole, UK).APC-labeled anti-human IFN-γ antibody was
purchased from eBioscience (Hatﬁeld, UK). Recombinant
human GM-CSF, IL-1β, IL-4, IL-6, TGF-β,a n dT N F - α were
obtained from R&D Systems (Abingdon, UK). Ionomycin,
PGE2 and phorbol 12-myristate 13-acetate (PMA) were
purchased from Sigma-Aldrich.
2.2. Peripheral Blood Samples. PBMC were obtained using
blood samples taken from healthy apheresis donors with
informed consent, and the Central and South Bristol
Research Ethics Committee approved the study.
2.3. Cell Line Culture. The KG-1 human AML cell line was
purchased from ECACC (Salisbury, UK). The cytokine-
dependent MUTZ-3 acute myelomonocytic leukaemia and
5637 cell lines were obtained from DSMZ (Braun-
schweig, Germany). KG-1 was cultured in Iscove’s modiﬁed
Dulbecco’s medium with GlutaMAX I (IMDM, Gibco-
Invitrogen, Paisley, UK) plus 20% (v/v) fetal bovine serum
(FBS, Sigma-Aldrich). MUTZ-3 was maintained in min-
imum essential medium-α (Gibco-Invitrogen) plus 20%
(v/v) FBS and 10% conditioned medium prepared from the
5637 bladder carcinoma cell line [14], which was cultured
in IMDM supplemented with 10% FBS (v/v). The 5637-
conditioned medium was collected, ﬁltered with a 0.2μm
syringe ﬁlter and kept at −80◦C for further use. All media
were supplemented with 100U/mL penicillin and 100μg/mL
streptomycin. The KG-1 and MUTZ-3 cells were passaged
routinely and grown in a humidiﬁed incubator at 37◦C
with 5% (v/v) CO2. HLA typing of KG-1 and MUTZ-3
cells was done by Department of Histocompatibility and
Immunogenetics, NHS Blood and Transplant. HLA type of
KG-1 cells is A30, B53, B78, Cw16, Cw04, DR11, DR14, and
DQ06, and the MUTZ-3 HLA type is A02, A03, B44, Cw04,
Cw07 and DR10, DR11, DQ03, DQ05.
2.4. Generation of DLC and DC. For generation of DLC,
either KG-1 or MUTZ-3 cells were seeded at 2 × 105/well in
24-well plates in IMDM containing 20% (v/v) BIT (StemCell
Technologies, Vancouver, Canada). PBMC were prepared
by Ficoll (Sigma-Aldrich) separation, suspended at either
106 cells/mL or 5 × 105 cells/mL, respectively, in IMDM
containing 20% (v/v) BIT and incubated for 3 hours on 2%
(v/v) human albumin precoated 6-well plates. Suspended
cells were then removed by replacing with fresh IMDM
supplemented with 20% BIT (v/v) and cytokines. DLC or
DC from KG-1, MUTZ-3, and PBMC were induced using
two culture methods: (i) FastDC method: 20ng/mL IL-
4 and 62.5ng/mL GM-CSF for 24 hours then maturation
with 9ng/mL TNF-α,1 0n g / m LI L - 1 β,1 0n g / m LI L - 6 ,a n d
350ng/mL PGE2 for another 24 hours [3]a n df o rK G - 1
DLC, cells were cultured for 24h with all FastDC cytokines
and 200ng/mL ionomycin; (ii) 7-day culture method, where
cells were stimulated with 20ng/mL IL-4, and 50ng/mL
GM-CSF for 5 days then with 12ng/mL TNF-α for 2 days
for maturation. During the culture, half the volume of
medium was replaced with fresh medium supplemented
with cytokines every other day. The cells were cultured in a
humidiﬁed incubator at 37◦C supplied with 5% (v/v) CO2.
2.5. Analyses by Flow Cytometry. The phenotypes of PBMC
and derived DC were monitored using a Coulter EPICS XL
ﬂow cytometer. Further data analysis was carried out using
Expo32 ADC software. The phenotypes of KG-1, MUTZ-3,
and their induced DLC as well as IFN-γ production were
analyzed using BD Calibur and data were processed using
WinMDI 2.9 software.
2.6. FITC-Dextran Uptake. Each cell sample was incubated
in the dark with FITC-dextran (1mg/mL) prepared with
HBSS either at 37◦Co ra t4 ◦C as control for 1hr and
were then washed with cold HBSS before being analyzed by
ﬂow cytometry. Results were expressed as the ratio of mean
ﬂuorescence intensity of each sample to its control culture at
4◦C.
2.7. Mixed Lymphocyte Culture (MLC) Assay. All cells were
washed once and resuspended in RPMI 1640 with 10% (v/v)
heat inactivated human AB serum (Sigma-Aldrich). MLCs
were set up in 96-well round-bottom plates by culturing
50,000 cells/well responder PBMC from HLA mismatched
donorswitheither25Gy 137Csγ-irradiatedallogeneicPBMC
and DC, 60Gy irradiated KG-1 and derived DLC or 80Gy
irradiated MUTZ-3 and derived DLC. The ﬁnal volume of
each well was 200μL, and all determinations were performed
in quadruplicate. Cell proliferation was assessed on day 5Journal of Biomedicine and Biotechnology 3
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Figure 1: DLC phenotypes of KG-1 cells. KG-1 cells were culture to generate DLC using FastDC and 7-day culture methods. The phenotypes
were monitored at immature (iDLC) and mature (mDLC) stages in each culture. Data are representative of at least three samples. Shaded
histograms are isotype controls and unshaded histograms represent marker expression.
Table 1:CellphenotypesofDCgeneratedfromPBMCusingFastDCand7-dayculturemethods.Theresultswerethepercentagesofpositive
stained cells in gated cells after subtraction of the appropriate values of isotype controls. Results are shown as mean ± SD, where n is the
total sample number tested.
Before culture (n = 19) FastDC 7-day culture
iDC (n = 6) mDC (n = 6) iDC (n = 4) mDC (n = 7)
CD1a 1.1 ±1.43 .0 ±1.51 7 .8 ±2.64 5 .3 ±17.13 1 .5 ±19.6
CD40 2.0 ±2.01 4 .4 ±4.45 6 .2 ±7.53 4 .5 ±8.34 4 .0 ±16.8
CD54 30.7 ±11.08 8 .1 ±4.29 4 .1 ±2.28 6 .2 ±4.67 7 .6 ±6.5
CD80 1.3 ±3.71 4 .9 ±7.04 7 .5 ±9.82 9 .4 ±5.93 1 .1 ±16.2
CD83 1.9 ±2.21 7 .7 ±5.16 1 .0 ±7.69 .3 ±7.12 6 .8 ±15.9
CD86 9.9 ±5.43 9 .1 ±11.77 6 .3 ±6.83 7 .5 ±12.14 8 .7 ±18.2
HLA-DR 21.9 ±6.68 2 .9 ±8.19 0 .9 ±3.46 9 .2 ±6.76 9 .5 ±11.4
HLA-ABC 97.1 ±3.99 8 .0 ±1.29 9 .3 ±0.79 3 .2 ±7.99 4 .5 ±2.2
CD1a+CD11c+ 0.8 ±1.03 .2 ±1.31 6 .0 ±1.73 2 .8 ±16.02 9 .6 ±19.5
CD1a+CD123+ 0.7 ±0.82 .6 ±1.21 4 .3 ±2.32 .3 ±1.54 .4 ±1.7
for KG-1 or day 7 for MUTZ-3 and derived DLC. DC
produced from PBMC FastDC culture were used for an MLR
course study from day 4 to 7. 4μCi/well of 3H thymidine
(GE Healthcare, Chalfont, Bucks, UK) were added into
culture at the last 18 hours. Cells were harvested onto ﬁlters
using a Tomtec harvester and then counted on a Wallac
Tailux 1450 microBeta counter. MLC results were calculated
after subtraction of the respective reading of 3H-thymidine
incorporated into the irradiated stimulator cells alone.
2.8. In Vitro IFN-γ Assay. In order to be distinguished from
stimulator cells, responder PBMC from HLA mismatched
donors were incubated with 5μMC F S Ea t3 7 ◦C for 20min.4 Journal of Biomedicine and Biotechnology
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Figure 2: DLC phenotypes of MUTZ-3. DLC generated from MUTZ-3 after culture using FastDC and 7-day culture methods. One
representative result from three experiments is shown. Isotype controls are shaded and surface markers are unshaded in histogram.
Irradiated KG-1, MUTZ-3, and their derived DLC and DC
generated from PBMC FastDC and 7-day cultures were
mixed with 5 × 104 responder PBMC at the ratio of 1:10
in each well in round-bottom 96-well plates. The plates
were cultured for 4 days and 10ng/mL PMA and 200ng/mL
ionomycin were added into the culture for the last 16hrs.
On the day of harvest, GolgiPlug (BD Biosciences) was
added to each well and incubated for 3 hours. The cells
were stained with CD8-PE antibody then resuspended in
BD Cytoﬁx/Cytoperm buﬀer to permeabilise for 20min at
4◦C. After washing with BD Perm/wash buﬀer, the cells were
stained with IFN-γ-APC antibody before analysis by ﬂow
cytometry.
2.9. Statistical Analysis. Statistical analysis was carried out
using one-way ANOVA followed by Dunnett’s test.
3. Results
3.1. DLC Phenotype Using Cultured KG-1 and MUTZ-3
Cells. Normal cultured KG-1 cells expressed high levels of
CD54, HLA-DR, and HLA-ABC and low levels of CD86,
but not CD1a, CD80, and CD83 (Figure 1). After culture
using the FastDC method, de novo expression of CD83
and upregulation of CD86 and CD54 were observed at the
maturationstage.Inthe7-daycultures,CD54expressionwas
increased but no CD83 expression was observed. Moderate
levels of expression of HLA-DR and a high level of HLA-
ABC were seen in both induction methods. Importantly the
DLC generated were not monocytes as conﬁrmed by the lack
of CD14 expression on their surface. Although there were
only minor diﬀerences between the phenotypes of the DCs
generated using FastDC and 7-day culture techniques, we
selected the FastDC method as this has been most frequently
described in the literature [15].
MUTZ-3 cells were also tested for their ability to
diﬀerentiate and display a DLC phenotype (Figure 2). After
maturation in both the FastDC and 7-day cultures, the
expression of CD14 observed on normal MUTZ-3 sur-
face disappeared. DLC derived from MUTZ-3 upregulated
expressionofCD54andCD86whileHLA-DRandHLA-ABC
expression remained constant throughout. Comparing the
two induction methods, there were higher expression levels
of CD1a, CD40, CD80, and CD83 in the 7-day culture. From
theseresultsthe7-dayculturemethodwaschosentogenerate
DLC from MUTZ-3 for functional experiments.
3.2. Phenotypic Characterization of DC Diﬀerentiated from
PBMC. PBMC from healthy blood donors were stimulated
using either FastDC or 7-day culture methods (Figure 3 and
Table 1).Beforeculture,PBMCexpressedlowlevelsofCD1a,
CD80, and CD83 and low levels of CD86 and HLA-DR
whereas after culture, expression of CD1a, CD80, and CD83
was increased on the iDC and were further elevated after
maturation of the DC. Improved levels of CD54, CD86, and
HLA-DR and high expression of MHC I was also observed
using both methods for both iDC and mDC (Table 1).
The highest levels of CD80, CD83, CD86, and HLA-DRJournal of Biomedicine and Biotechnology 5
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Figure 3:FlowcytometricanalysesofiDCandmDCgeneratedfromPBMCofthesamedonorusingtheFastDCand7-dayculturemethods.
PBMC freshly prepared from one donor were analysed before culture and then were cultured for DC generation using both the FastDC and
7-daymethods.InFastDCculturecellswereculturedinIL-4andGM-CSFforﬁrst24hrsfollowedbyanother24hrstomatureDCinTNF-α,
IL-1β, IL-6, and PGE2. In 7-day culture, PBMC were stimulated in IL-4 and GM-CSF at iDC stage for 5 days then with TNF-α for 2 days
to obtain mDC. Data are representative of at least three samples. Unshaded histograms drawn with broken lines are isotype controls and
shaded histograms represent marker expression.
expression were observed amongst mDC after 2-day culture.
Diﬀerentiation into myeloid DC (myDC) and plasmacytoid
DC (pDC) subtypes was deﬁned using CD1a+CD11c+ and
CD1a+CD123+, respectively, to delineate the two subsets.
In FastDC culture, percentages of both myDC and pDC
increased during the culture period and reached a similar
levelatmaturestage.In7-dayculturethereweremoremyDC
than pDC at the end of culture (Table 1). In addition it was
found that the cell output number was highest in PBMC
FastDC culture (data not shown).
3.3. Dextran-FITC Uptake. Endocytosis is a functional fea-
ture of iDC, which decreases with maturation. iDC from
PBMC demonstrated high endocytotic capability in both
FastDC and 7-day culture with ratios > 2c o m p a r e dt o
4◦Cc o n t r o lf o re a c hm e a s u r e m e n t( Figure 4). However,
DLC derived from KG-1 or MUTZ-3 showed only minimal
increase in Dextran-FITC uptake (Figure 4).
3.4. MLC Experiments Using DLC and DC Stimulator Cells.
DLC derived from either KG-1 or MUTZ-3 and their
unmodiﬁed cells were used as stimulators after irradiation to
inhibit their growth (see above) although some proliferation
could still be detected after irradiation, particularly in the
ﬁrst 3 days of culture (data not shown). Unmanipulated
KG-1 cells were able to cause moderate PBMC stimulation
(Figure 5(a)); as illustrated by the fact that proliferation
of responder cells (>10,000cpm) was only observed at
high stimulator-to-responder ratios (1:1, 1:10). In contrast,
DLC produced from KG-1 cells showed enhanced ability
to stimulate allogeneic PBMC responder cells. Likewise,
MUTZ-3 DLC but not unmodiﬁed MUTZ-3 cells stimu-
lated allogeneic T-cell proliferation in MLR (Figure 5(b)).
Allogeneic DC produced from FastDC culture signiﬁcantly
increased the proliferation of PBMC (Figure 6(a)). The
ability of generated DC to cause T-cell proliferation was
superior to that of PBMC. The proliferation of PBMC after
coculture with allogeneic DC from FastDC cultures was
measured between day 4 and day 7 and was maximal on day
7( Figure 6(b)).
3.5. IFN-γ Production from Allogeneic T Cells Stimulated
with DLC. When KG-1 and MUTZ-3 DLC were cocultured
with allogeneic T cells, they stimulated production of IFN-γ
which was greater than that seen with unmodiﬁed KG-1 and
MUTZ-3cells,(Figure 7).TheincreaseinIFN-γ stainingwas
more marked for MUTZ-3 DLC. In addition, DC obtained
from FastDC and 7-day cultures stimulated responder CD8+
Tc e l lI F N - γ production to similar levels. In the culture of6 Journal of Biomedicine and Biotechnology
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Figure 4: Dextran uptake of immature DC from PBMC and DLC
diﬀerentiatedfromKG-1andMUTZ-3cells.Dextranuptakeofeach
sample was detected by ﬂow cytometry after 1hr of incubation at
37◦Co ro ni c ea n dM F Ir a t i oi sp r e s e n t e d .T e s t sw e r ec a r r i e do u t
in PBMC on day 1 of FastDC (FastDC iDC) and day 5 of 7-day
culture (7D iDC), as well as diﬀerentiated DLC from KG-1 (KD
DLC) and MUTZ-3 cells (MUTZ DLC) via FastDC culture and 7-
day culture, respectively. Results are shown as mean ± SEM, at least
three samples were tested.
responder alone, after PMA and ionomycin stimulation for
16hrs, IFN-γ level was only about 1% of gated CD8+ Tc e l l s
(data not shown).
4. Discussion
The use of DLC derived from leukemic cells to stimulate
tumor antigen-speciﬁc T-cell responses is of considerable
interest.InvestigationofCTLresponsestoleukemiccellsmay
be hampered by lack of material, and the use of leukemic
cell lines may allow a greater number of experiments to
be performed, although selection of HLA-matched donors
may be problematic with leukemia cell lines of unusual HLA
type. The potential of AML cells to develop into DLC may
be determined by their stage of lineage commitment and
therefore this may be related to the clinical classiﬁcation of
the leukemia from which they are derived [16]. Previous
reports have shown varying degrees of DLC development
from the KG-1 and THP-1 cell lines which show myeloid
and monocytic lineage commitment, respectively [9, 16].
The myelomonocytic cell line, U937 fails to readily produce
DLC probably because it has progressed too far along the
macrophage diﬀerentiation pathway and undiﬀerentiated
leukemias are also of limited utility, producing less than
10% DLC [16]. Reports indicate that the MUTZ-3 cell line
which shows intermediate diﬀerentiation is readily able to
undergo DLC diﬀerentiation [17]. The results of this study
concur with other reports and show that KG-1 cells can
be converted into DLC following stimulation with IL-4,
GM-CSF, TNF-α,I L - 1 β,I L - 6 ,a n dP G E 2. Culture using the
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Figure 5: 3H-thymidine incorporation in MLC of DLC generated
from KG-1 and MUTZ-3 cells. The MLC measurement was carried
out after coculture with KG-1 (a) and MUTZ-3 (b) to check the
donor PBMC proliferation. DLC were obtained from either KG-1
cells (KG-DLC) using FastDC culture or MUTZ-3 cells (MUTZ-
DLC) using 7-day culture, and the proliferation stimulated by DLC
was compared with that of normal KG-1 or MUTZ-3 cells. Results
areexpressedasmean ±SEM,n = 3forusingPBMCcollectedfrom
three donors. ∗P<0.05 compared with KG-1.
FastDC method induced de novo expression of CD83 and
up-regulation of CD86 and CD54. Failure to express CD1a is
consistent with the ﬁndings of another report [10]. MUTZ-
3 DLC upregulated expression of CD54 and CD86 using
the 7-day culture method but there was a slight increase in
CD1a, CD40, CD80, and CD83. Our data suggest that the
FastDCmethodissuitablefordirectDCculturefromPBMC.
Both FastDC and the 7-day culture methods induced expres-
sion of CD1a, CD54, CD80, CD83, CD86, and HLA-DR.Journal of Biomedicine and Biotechnology 7
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Figure 6: 3H-thymidine incorporation in MLCs using PBMC-
derived DC. MLC measurement was carried out after coculture for
4 days using DC generated from PBMC by FastDC (a). In the same
experiment, allogeneic DC were compared with allogeneic PBMC
for their stimulation ability, as well as with autologous DC. DC
produced from FastDC culture were also used for an MLC time
coursestudyfromday4today7(b).Resultsaremean ±SEM,n = 3
for three tested samples. ∗P<0.05, ∗∗P<0.01 compared with
allogeneic PBMC; +P<0.05, ++P<0.01 compared with autologous
DC.
The expression of CD54, CD80, CD83, CD86, and HLA-DR
was highest in 2-day cultures. In previous reports the FastDC
method was only employed to culture DC from CD14
selectedmonocytes[17].Ourﬁndingsareinaccordancewith
an earlier study by Teobald et al., in which upregulation of
CD86byactivatedKG-1cellswasalsogreaterthanCD83and
CD80 [18]. In contrast, another study showed that although
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Figure 7: IFN-γ production from CD8+ T cells. Irradiated KG-1
(a), MUTZ-3 (b) and the derived DLC as well as FastDC and 7-day
culture DC derived from PBMC (c) were cocultured at the ration of
1:10 for 4 days with 5 × 105 responder PBMC loaded with CFSE.
Before cells were harvested for IFN-γ assay, 10ng/mL PMA and
200ng/mL ionomycin were added into the culture for the last 16hrs
of incubation. Cells analysed were gated on CFSE positive CD8+ T
cells. One representative result is shown.
CD80 and CD83 were not expressed on unstimulated KG-1
cells they were up-regulated following activation [10].
CD83 is known to be up-regulated amongst monocyte-
derived DC and by MUTZ-3 cells following culture using the
conventional 7-day protocol [19]. Although our results are
consistentwiththeseﬁndings,followingtheFastDCprotocol
MUTZ-3 DLC failed to express CD83 as well as CD80 and
CD86.Onepossibleexplanationisthatthese“FastDLC”may
not be fully activated. We suggest that this is unlikely, given
the fact that they were unable to endocytose FITC-labeled8 Journal of Biomedicine and Biotechnology
dextran, and they were capable of eliciting IFN-γ production
by na¨ ıve T cells.
In critical assays measuring DC function, we showed that
DLC derived from both AML cell lines showed enhanced
ability to stimulate proliferation in MLC. Moreover the
production of IFN-γ from KG-1 and MUTZ-3 DLC was
signiﬁcantly elevated when compared to control (unmodi-
ﬁed) KG-1 and MUTZ-3 cells. Conventional DC generated
using both FastDC and 7-day culture were able to phagocy-
tose FITC-labeled dextran and stimulate HLA mismatched
allogeneic responder cells better than unmodiﬁed PBMC
stimulators. In previous in vitro functional studies, it was
shown that FastDC derived from normal PBMC secrete IL-
12 (p70) when ligated with CD40 in the presence of IFN-
γ, induce antigen-speciﬁc T-cell proliferation and IFN-γ
production, and prime tumor antigen-speciﬁc cytotoxic T-
cells [3, 15]. Another immunotherapeutic approach using ex
vivo culture of AML cells to generate functional DC is of
greatinterest;havingtheadvantagethatDLCgeneratedfrom
patient AML cells will present tumour antigens to donor
T cells to stimulate CTL responses. In patient with acute
leukaemia eﬀective DC responses are often impaired and the
absolute number of DC is reduced in children with acute
lymphoblastic leukemia [20]. The tumor microenvironment
may be inhibitory to growth of functional DC [16, 21]; this
may include defective T-cell activation as a result of a lack of
crucial cell-cell signaling.
The signal pathways involved in DC activation are still
not fully understood. Under pathological conditions the
situation is more complex as the gene expression proﬁles and
signaling pathways may be altered [22, 23]. In KG-1 cells,
the protein kinase C (PKC) pathway is an important signal
transduction route for DLC activation and inhibition of PKC
may abort DLC induction [10]. Although Toll-like receptor
4 (TLR4) is expressed by MUTZ-3 cells the TLR pathway
is impaired so LPS cannot stimulate the maturation of DLC
diﬀerentiated from MUTZ-3 [24]. Other studies have shown
that after culturing AML blasts for a short time with calcium
ionophore DLC could be obtained which highly expressed
the DC-related surface molecules such as CD80, CD83,
CD86, and HLA-DR and which had the ability to promote
CTL responses to blast cells [7, 25]. These intracellular signal
pathways control diﬀerent DC functions such as surface
antigen expression, cytokine secretion, and DC migration
[26]. DC maturation after stimulation depends on the total
outcome of the interactive network of signal transduction.
Studies showed that human leukemic cell lines such as
KG-1 might diﬀerentiate into DLC of mature phenotypes
directly, bypassing the immature phase [10, 11]. This direct
maturation of KG-1 after culture with PMA and ionomycin
not only increases the expression of CD83 as a maturation
surface marker, but decreases the ability of endocytosis [18].
In our study, DLC diﬀerentiated from KG-1 or MUTZ-3
cells did not show improved endocytosis, and uptake level
of Dextran-FITC was less than undiﬀerentiated KG-1 or
MUTZ-3 (data not shown). Previous reports showed that
DLC generated from MUTZ-3 include two stages: culture
with GM-CSF, IL-4, and low dose of TNF-α to obtain
immature DLC and further high-dose TNF-α treatment to
induce the maturation [17]. In this study, we observed some
increase in the levels of DC-related surface markers after
maturation in 7-day culture.
We conclude that phenotypic DLC can be derived from
the AML cell lines KG-1 and MUTZ-3 and that these induce
CTL responses. Moreover, FastDC culture could be utilised
t og e n e r a t eD Cf r o mP B M Ca sw e l la sC D 1 4 + selected
cells and these were capable of promoting allogeneic PBMC
proliferation up to day 7. These ﬁndings will be of great
importance in determining the choice of cells and culture
conditions for the development of future immunotherapeu-
tic strategies to combat AML and other cancers.
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